Statistics for Cost utility analysis of long acting muscarinic antagonists (LAMAs) as an alternative to long acting beta agonists (labas) for treatment of severe COPD in the South African public sector

Total visits

views
Cost utility analysis of long acting muscarinic antagonists (LAMAs) as an alternative to long acting beta agonists (labas) for treatment of severe COPD in the South African public sector 10

Total visits per month

views
November 2023 0
December 2023 0
January 2024 0
February 2024 3
March 2024 7
April 2024 0
May 2024 0

File Visits

views
MPH_COMH7175A_1946476_03.06.2023.pdf 25

Top country views

views
South Africa 9
Norway 1

Top city views

views
Johannesburg 7
Lenasia 2